Skip to content

Evidence based evaluation of Qizhi Jieyu Pill in the treatment of cerebral infarction in the recovery period - a randomized controlled clinical study of Qizhi Jieyu Pill in the treatment of cerebral infarction in the recovery period (phlegm blood stasis obstruction syndrome)

Evidence based evaluation of Qizhi Jieyu Pill in the treatment of cerebral infarction in the recovery period - a randomized controlled clinical study of Qizhi Jieyu Pill in the treatment of cerebral infarction in the recovery period (phlegm blood stasis obstruction syndrome)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000653
Enrollment
Unknown
Registered
2025-04-06
Start date
2025-04-15
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral infarction

Interventions

control group:Conventional Western Medicine Treatment
study group:Conventional Western Medicine Treatment+Qizhi Jieyu Pill

Sponsors

Guang'anmen Hospital Chinese Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Complies with the diagnosis of cerebral infarction and belongs to the recovery period of the disease; (2) Age range from 30 to 70 years old; (3) Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Head CT or MRI diagnosis of intracranial hemorrhagic diseases; (2) Patients with abnormal laboratory tests: ALT AST = 2.5 times the upper limit of normal Cr>upper limit of normal; (3) Unable to understand and/or follow research procedures due to severe mental cognitive or emotional disorders; (4) The combination of other diseases that affect limb activity may affect the neurofunctional evaluator; (5) Women who have fertility plans during pregnancy lactation or in the near future; (6) Suspected or confirmed history of alcohol or drug abuse within 6 months prior to onset of illness; (7) Individuals who are known or suspected to be allergic to the investigational drug or have an allergic constitution; (8) Individuals who have participated in other clinical trials within the past 3 months; (9) According to the researcher's judgment there are other situations that may reduce the likelihood of inclusion or complicate inclusion.

Design outcomes

Primary

MeasureTime frame
NHISS Stroke Scale Score;

Secondary

MeasureTime frame
Rankin Scale;Traditional Chinese Medicine Syndrome Points;Recurrence rate of cerebral infarction;

Countries

china

Contacts

Public Contactan xuedong

Guang'anmen Hospital Chinese Academy of Traditional Chinese Medicine

doctor_anxd@163.com19801207372

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026